Schaller M D
Département de médecine interne, CHUV, Lausanne.
Schweiz Med Wochenschr. 1992 May 16;122(20):768-75.
To reduce the very high mortality rate due to septic shock, a new clinical entity has been defined: sepsis syndrome. The aggressive treatment of any sepsis syndrome should prevent the evolution towards a state of shock and thus reduce the risk of a fatal outcome. It consists in broad spectrum antibiotic therapy associated with hemodynamic support (volume resuscitation, vasopressors and inotropic agents) at the first signs of cardiocirculatory failure. Several pharmacological or immunological interventions--antagonists directed at mediators and multiple cytokines involved in the pathogenesis and perpetuation of sepsis syndrome and septic shock--have been successful experimentally. However, new therapies, such as those using monoclonal antibodies against endotoxins of TNF, cannot yet be considered established.
为降低因感染性休克导致的极高死亡率,已定义了一种新的临床实体:脓毒症综合征。对任何脓毒症综合征进行积极治疗应可防止其发展为休克状态,从而降低致命结局的风险。其治疗方法包括在出现心循环衰竭的最初迹象时,采用广谱抗生素治疗并辅以血流动力学支持(容量复苏、血管升压药和正性肌力药物)。一些药理学或免疫学干预措施——针对参与脓毒症综合征和感染性休克发病机制及持续过程的介质和多种细胞因子的拮抗剂——在实验中已取得成功。然而,诸如使用抗TNF内毒素单克隆抗体的新疗法,目前仍不能视为已确立的疗法。